BridgeMD
New treatment option for Healthy
Official title A Study to Learn How a Single Dose of the Study Medicine Called PF-08057418 is Tolerated in the Body of Healthy Adults.
ClinicalTrials.gov ID: NCT07575906
What this study is testing
What is PF-08057418?
PF-08057418 is an investigational medicine, given as an once-weekly pill taken by mouth, being studied as a potential treatment for healthy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this clinical trial is to learn about the safety and pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from body after participant take it) of the study medicine (called PF-08057418) in healthy people. This study is seeking participants who are healthy adults.
- Phase 1: an early, usually small safety study
- Time commitment: about 13 weeks
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60. Healthy volunteers may be eligible.
You may be able to join if
- Adults 18 to 60 years of age (or the minimum age of consent per local regulations) at screening.
- Healthy participants, as determined by medical history, physical examination, clinical laboratory tests, and cardiac monitoring.
- Body mass index (BMI) between 16 and 32 kg/m² and body weight \>50 kg (110 lb).
- Willing and able to comply with all study procedures, including scheduled visits, treatment plans, laboratory testing, and lifestyle restrictions.
You likely can't join if
- History or evidence of clinically significant medical conditions, including but not limited to hematological, renal, endocrine, pulmonary...
- Any condition that may affect drug absorption (e.g., gastrectomy, cholecystectomy).
- History of HIV infection, hepatitis B, or hepatitis C, or positive screening tests for HIV, hepatitis B core antibody (HBcAb), hepatitis B surface...
- History of phototoxicity or photosensitivity.
- Prior use of any investigational drug or vaccine within 30 days or 5 half-lives (whichever is longer) before the first study dose, or participation...
- Elevated blood pressure at screening:
See the full eligibility criteria
- Adults 18 to 60 years of age (or the minimum age of consent per local regulations) at screening.
- Healthy participants, as determined by medical history, physical examination, clinical laboratory tests, and cardiac monitoring.
- Body mass index (BMI) between 16 and 32 kg/m² and body weight \>50 kg (110 lb).
- Willing and able to comply with all study procedures, including scheduled visits, treatment plans, laboratory testing, and lifestyle restrictions.
- History or evidence of clinically significant medical conditions, including but not limited to hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or...
- Any condition that may affect drug absorption (e.g., gastrectomy, cholecystectomy).
- History of HIV infection, hepatitis B, or hepatitis C, or positive screening tests for HIV, hepatitis B core antibody (HBcAb), hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb). Hepatitis B...
- History of phototoxicity or photosensitivity.
- Prior use of any investigational drug or vaccine within 30 days or 5 half-lives (whichever is longer) before the first study dose, or participation in another investigational study during this study.
- Elevated blood pressure at screening:
- 140/90 mm Hg for participants \<60 years, or
- 150/90 mm Hg for participants ≥60 years, after at least 5 minutes of supine rest (average of 3 measurements).
- Renal impairment, defined as estimated glomerular filtration rate (eGFR) \<75 mL/min/1.73 m².
- Clinically significant ECG abnormalities, including but not limited to QT corrected for heart rate by Fridericia's cube root formula (QTcF) \>450 ms, complete left bundle branch block, evidence of myocardial infarction...
- Clinically significant laboratory abnormalities at screening, including ALT, AST, or total bilirubin ≥1.05 × ULN (participants with Gilbert's syndrome may be eligible if direct bilirubin is ≤ULN).
The study team makes the final eligibility decision.
Where it's taking place
- New Haven, Connecticut, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 13 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Haven, Connecticut, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.